IP Verse

Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer

EP3791896

ASTELLAS PHARMA INC.
Application Number
EP20194625A
Filing Date
May 21, 2013
Status
Granted And Under Opposition
Dec 8, 2023
Grant Date
Jan 10, 2024
External Links
Slate, Register

Biblio Summary

The patent EP3791896B1 was granted on Jan 10, 2024 by Astellas Pharma Inc. The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 3 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DR. H. ULRICH DORRIESOct 10, 2024ADMISSIBLE
DR. STRAUS, ALEXANDEROct 10, 2024ADMISSIBLE
MAIWALD GMBHOct 8, 2024ADMISSIBLE

More Opposed Patents of Astellas Pharma Inc.

The table below shows the patents of Astellas Pharma Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3318259Stable Pharmaceutical Composition For Oral AdministrationJan 11, 20232
EP3725810Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerJul 6, 20222
EP3725778Formulations Of EnzalutamideAug 18, 202111

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents